Androstenedione is the preferred androgen source in hormone refractory prostate cancer Letter

Clinical Cancer Research

Volumn 20, Issue 18, 2014, Pages 4971-

  Sharifi, Nima ^a,b   Auchus, Richard J ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; ANTIANDROGEN;

DRUG RESISTANCE; HUMAN; MALE; METABOLISM; PHYSIOLOGY; PROSTATIC NEOPLASMS;

ANDROGEN ANTAGONISTS; ANDROGENS; ANDROSTENEDIONE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84907438022     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1123     Document Type: Letter

References (3)

1. Fankhauser M, Tan Y, Macintyre G, Haviv I, Hong MK, Nguyen T, et al. Canonical androstenedione reduction is the predominant source of signalling androgens in hormone refractory prostate cancer. Clin Cancer Res 2014 Apr 25. [Epub ahead of print].
2. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2011;108:13728-33.
3. Thigpen AE, Cala KM, Russell DW. Characterization of Chinese hamster ovary cell lines expressing human steroid 5 alpha-reductase isozymes. J Biol Chem 1993;268:17404-12.